Research ExplorerPublicationsBevacizumab induces regression of vestibular schwannomas in ...

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

Standard

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. / Mautner, Victor-Felix; Nguyen, Rosa; Kutta, Hannes; Fuensterer, Carsten; Bokemeyer, Carsten; Hagel, Christian; Friedrich, Reinhard E; Panse, Jens.

In: NEURO-ONCOLOGY, Vol. 12, No. 1, 01.01.2010, p. 14-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mautner, V-F, Nguyen, R, Kutta, H, Fuensterer, C, Bokemeyer, C, Hagel, C, Friedrich, RE & Panse, J 2010, 'Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2', NEURO-ONCOLOGY, vol. 12, no. 1, pp. 14-8. https://doi.org/10.1093/neuonc/nop010

APA

Mautner, V-F., Nguyen, R., Kutta, H., Fuensterer, C., Bokemeyer, C., Hagel, C., Friedrich, R. E., & Panse, J. (2010). Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. NEURO-ONCOLOGY, 12(1), 14-8. https://doi.org/10.1093/neuonc/nop010

Vancouver

Mautner V-F, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. NEURO-ONCOLOGY. 2010 Jan 1;12(1):14-8. https://doi.org/10.1093/neuonc/nop010

Bibtex

@article{2d827a255a19434baf99edc3cfe2115e,
title = "Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2",
abstract = "Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.",
keywords = "Adolescent, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Audiometry, Hearing Loss, Humans, Magnetic Resonance Imaging, Male, Neurofibromatosis 2, Neuroma, Acoustic, Young Adult",
author = "Victor-Felix Mautner and Rosa Nguyen and Hannes Kutta and Carsten Fuensterer and Carsten Bokemeyer and Christian Hagel and Friedrich, {Reinhard E} and Jens Panse",
year = "2010",
month = jan,
day = "1",
doi = "10.1093/neuonc/nop010",
language = "English",
volume = "12",
pages = "14--8",
journal = "NEURO-ONCOLOGY",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

AU - Mautner, Victor-Felix

AU - Nguyen, Rosa

AU - Kutta, Hannes

AU - Fuensterer, Carsten

AU - Bokemeyer, Carsten

AU - Hagel, Christian

AU - Friedrich, Reinhard E

AU - Panse, Jens

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.

AB - Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.

KW - Adolescent

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Agents

KW - Audiometry

KW - Hearing Loss

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Neurofibromatosis 2

KW - Neuroma, Acoustic

KW - Young Adult

U2 - 10.1093/neuonc/nop010

DO - 10.1093/neuonc/nop010

M3 - SCORING: Journal article

C2 - 20150363

VL - 12

SP - 14

EP - 18

JO - NEURO-ONCOLOGY

JF - NEURO-ONCOLOGY

SN - 1522-8517

IS - 1

ER -